Search results
We Think Shareholders May Want To Consider A Review Of Moderna, Inc.'s (NASDAQ:MRNA) CEO...
Simply Wall St. via Yahoo Finance· 6 days agoKey Insights Moderna to hold its Annual General Meeting on 6th of May CEO Stephane Bancel's total...
Moderna (MRNA) Q1 2024 Earnings Call Transcript
Motley Fool via Yahoo Finance· 3 days agos first-quarter 2024 financial results and business updates. You can access the press release issued this morning as well as the slides that we'll be...
Moderna beats estimates in Q1 2024, targets RSV vaccine launch in fall By Investing.com
Investing.com· 4 days agoModerna Inc. (NASDAQ:MRNA) reported first-quarter earnings and revenue that came ahead of analyst...
Moderna loses less than expected as Covid vaccine sales beat estimates, cost cuts take hold
CNBC· 4 days agoModerna on Thursday posted a narrower-than-expected loss for the first quarter as the company's...
Moderna Reports Smaller Than Expected Q1 Loss, Prepares For RSV Vaccine And Spikevax 2024-2025...
Benzinga via Yahoo Finance· 3 days agoThursday, Moderna Inc (NASDAQ:MRNA) reported a first-quarter EPS loss of $(3.07), down from an...
Moderna’s sales from its only product, the COVID-19 vaccine, fell 91% from last year
Fortune via Yahoo Finance· 3 days agoThose products could range from RSV vaccines to individualized cancer treatments, which will help...
Merck Reports Progress On The Cancer Front As It Prepares For Keytruda Patent Expiration
Benzinga via Yahoo Finance· 3 days agoAfter topping expectations with first quarter revenue and adjusted earnings last week, Merck & Co...
Moderna stock surges 15% after it beat earnings expectations despite plummeting COVID vaccine sales
Quartz· 4 days agoModerna stock soared on Thursday after its first-quarter earnings report sailed past Wall Street’s...
Biotech Innovations Aim to Combat Soaring Cancer Diagnoses by 2050
FOX 59 Indianapolis· 5 days agoUSA News Group – An alarming trend is happening around the world, where tens of millions of...
Moderna COVID vaccine sales plummet 91 percent - The Boston Globe
The Boston Globe· 4 days agoSales of Moderna’s COVID-19 vaccine plunged 91 percent from the previous year for the first quarter...
